We understand poor pre-formulation studies may lead to delays in pre-clinical and clinical development programs. With our world-leading expertise in development of methods for inhaled drug product characterisation, we can provide the solid foundation required for successful transition of early phase development programs through to clinical.
Orally inhaled and nasal drug products are complex systems that are highly dependent on interactions between device and formulation components. Our INTERHALE technologies offer a range of tailored and robust formulation development solutions for all types of pMDIs and DPI device platforms.
Nanopharm was founded on its advanced analytical characterisation services and its understanding of how input material physico-chemical and mechanical properties affect product specification, functionality and stability of orally inhaled and nasal drug products.